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During asexual intraerythrocytic growth, Plasmodium falciparum utilizes hemoglobin obtained from the host
red blood cell (RBC) as a nutrient source. Papain-like cysteine proteases, falcipains 2 and 3, have been
reported to be involved in hemoglobin digestion and are targets of current antimalarial drug development
efforts. However, their expression during gametocytogenesis, which is required for malaria parasite transmis-
sion, has not been studied. Many of the available antimalarials do not inhibit development of sexual stage
parasites, and therefore, the persistence of gametocytes after drug treatment allows continued transmission of
the disease. In the work reported here, incubation of stage V gametocytes with membrane-permeant cysteine
protease inhibitor E64d significantly inhibited oocyst production (80 to 100%). The same conditions inhibited
processing of gametocyte-surface antigen Pfs230 during gametogenesis but did not alter the morphology of the
food vacuole in gametocytes, inhibit emergence, or block male exflagellation. E64d reduced the level of oocyst
production more effectively than that reported previously for falcipain 1-knockout parasites, suggesting that
falcipains 2 and 3 may also be involved in malaria parasite transmission. However, in this study only falcipain
3 and not falcipain 2 was found to be expressed in stage V gametocytes. Interestingly, during gametocytogenesis
falcipain 3 was transported into the red blood cell and by stage V was localized in vesicles along the RBC
surface, consistent with a role during gamete emergence. The ability of a membrane-permeant cysteine
protease inhibitor to significantly reduce malaria parasite transmission suggests that future drug design
should include evaluation of gametogenesis and sporogonic development.
The clinical symptoms of malaria are caused by asexually
replicating parasites, but malaria parasite transmission re-
quires that a subpopulation of parasites undergo sexual differ-
entiation. In the species of parasite responsible for the most
virulent form of malaria, Plasmodium falciparum, complete
maturation into mature stage V gametocytes takes 10 to 12
days in the human host. Once stage V gametocytes are taken
up by a mosquito, gametogenesis is stimulated and, after fer-
tilization, the zygote differentiates into an ookinete. The ooki-
nete then migrates to the basal surface of the midgut and forms
an oocyst, where tens of thousands of infectious sporozoites
are produced.
Both asexual and sexual stage parasites are present concur-
rently in an infected individual and therefore would both be
exposed to antimalarial drugs. However, gametocytes have
been found to be resistant to many of the commonly used
antimalarials, such as the 4-aminoquinolines; and sulfadoxine-
pyrimethamine has been reported to increase the production
of gametocytes, which could enhance transmission (2, 12, 21,
36). Consequently, even after successful treatment for clinical
symptoms, an individual can still transmit the malaria parasite
for at least a week. Therefore, it is important to develop ther-
apeutic agents that effectively inhibit both asexual and sexual
stage parasites.
Cysteine proteases are currently being developed as drugs
that target asexual parasites (27). Treatment of trophozoites
with specific cysteine protease inhibitors, such as E64, peptidyl
fluoromethyl ketones (FMKs), and peptidyl vinyl sulfones
(VSs), block hemoglobin digestion, causing distension of the
food vacuole and inhibition of schizont production (25, 30, 34).
Cysteine protease inhibitors have also been shown to interfere
with, but not completely block, merozoite release and to inhibit
P. berghei and P. falciparum sporozoite invasion (4, 28, 37).
Membrane-permeant E64d has also been shown to inhibit the
processing of the 360-kDa P. falciparum gametocyte surface
antigen Pfs230 to 35-kDa and 300-kDa fragments during ga-
metogenesis, while the production of the 47-kDa and the 307-
kDa fragments is not affected. When the parasite emerges
from the red blood cell (RBC) as a gamete in the mosquito
midgut, 35-kDa and 47-kDa sections of the first 555 amino
acids (aa) of Pfs230, which includes the immunodominant glu-
tamate-rich repeat domains, are released as soluble fragments
(3, 24). In contrast, the 300-kDa and 307-kDa fragments re-
main associated with the gamete surface and are the targets of
malaria parasite transmission-blocking monoclonal antibodies
(3, 38).
Four papain-like cysteine proteases have been identified in
the P. falciparum genome and have been named falcipains 1,
2A, 2B, and 3 (18, 27). The gene for falcipain 1 was cloned first,
and although it is expressed in asexual parasites, mRNA levels
have been found to increase during sexual differentiation (8,
26). Indeed, targeted gene disruption does not affect asexual
growth but significantly decreases oocyst production (8). Fal-
cipains 2A and 2B share 97% amino acid identity and there-
fore are difficult to differentiate with immunological reagents
(18). By using specific oligonucleotide probes, falcipain 2B
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mRNA was found to be expressed at a lower level than fal-
cipain 2A. However, falcipains 2A and 2B have similar time
courses of expression and their expression peaks at the late
trophozoite stage, which suggests that the two falcipain 2 genes
may have similar roles (35). Falcipains 2A and 3 have been
proposed to be involved in hemoglobin digestion, since they
have been located in the food vacuole and the corresponding
recombinant proteins have acidic pH maxima and can degrade
denatured hemoglobin (31, 34). Additionally, targeted disrup-
tion of the falcipain 2A gene was recently reported to cause
distention of the food vacuole in trophozoites (33). This phe-
notype is similar to that induced by treatment with cysteine
protease inhibitor E64. The disruption of falcipain 2B had no
detectable effect on the food vacuole or asexual growth (32). In
contrast, the disruption of falcipain 3 has not been reported,
although it has been attempted by our group and other inves-
tigators (32). This could indicate that falcipain 3 is essential for
asexual growth, as would be expected for a gene that is re-
quired for the digestion of hemoglobin, which is a major source
of nutrition for asexual parasites and very early gametocytes.
Although the protein expression patterns of falcipain 2A,
2B, and 3 have been well studied in asexual parasites, they have
not been characterized in gametocytes. It has been reported
that the rate of hemoglobin digestion decreases after day 4 of
gametocytogenesis, which corresponds to early stage II, and
that hemoglobin digestion may not be necessary for further
sporogonic development (14). The work reported here found
that falcipain 3 and not falcipain 2A or 2B was expressed
throughout gametocytogenesis and was exported into the RBC
during gametocyte maturation. Protease inhibitors were then
used to evaluate the role of cysteine proteases in malaria par-
asite transmission and their potential as drug targets.
MATERIALS AND METHODS
P. falciparum parasites. P. falciparum strain 3D7 parasites were maintained in
culture, and gametocytogenesis was induced as described by Ifediba and Vander-
berg (13). Cultures containing mature stage V gametocytes were incubated at 37°C
in complete RPMI 1640 (Invitrogen, Carlsbad, CA) for the indicated time with
or without protease inhibitors, 100 M E64d (Sigma, St Louis, MO), 10 M
YA29 (generously provided by M. Bogyo and D. Greenbaum) (10), and 10 M
morpholine urea-leucine-homophenylalanine-phenolvinylsulfone (Mu-Leu-hPhe-
VSPh) and 10 M morpholine urea-leucine-homophenylalanine-fluoromethyl-
ketone (Mu-Leu-hPhe-FMK) (generously provided by P. Rosenthal) (29).
Gamete/zygote production and exflagellation were induced by resuspending the
mature stage V gametocytes in an equal volume of emergence medium (10 M
xanthurenic acid, 1.67 mg ml1 glucose, 8 mg ml1 NaCl, 8 mM Tris-Cl [pH 8.2])
at room temperature (RT). After 1 h the medium and cell pellet were harvested
separately by centrifugation at 2,000  g for 3 min. The medium was further
clarified by centrifugation at 14,000  g for 10 min. The samples were stored
frozen until they were assayed for Pfs230 processing by sodium dodecyl sulfate
(SDS)-polyacrylamide gel electrophoresis (3).
Mosquito feeding assay. Cultures of P. falciparum parasites comprising isolate
NF54 (Table 1) or; strain 3D7 (Table 1 [see also Fig. 4A]) and containing mature
stage V gametocytes incubated with or without protease inhibitors (0.3 ml) were
pelleted onto 150 l packed erythrocytes (19). The supernatant was replaced
with 120 l of normal human serum containing active complement, mixed, and
introduced into a water-jacketed membrane feeder maintained at 39°C (20).
Anopheles stephensi (strain SxK Nij) mosquitoes were allowed to gorge for 10 min
and were then grown for 7 more days at 26  1°C and 80%  10% humidity.
The midguts were then dissected and stained in 1.0% mercurochrome to visu-
alize the P. falciparum oocysts (magnification, 100 to 200). The 3D7 feedings
were performed at Loyola University Chicago, and the NF54 feedings were
performed at the University of Nijmegen.
Antibodies. Falcipain 2A/B-specific antibodies were generously provided by P.
Rosenthal (34), and glycophorin A-specific antibodies were obtained from
Sigma. Pfs230 region A (aa 304 to 378)-specific antibodies were generated as
described by Williamson et al. (38). Falcipain 3-specific antibodies against a
recombinant maltose-binding protein–falcipain 3 (aa 249 to 502) fusion protein
were generated in mice. The coding sequence of falcipain 3 (aa 249 to 502) was
amplified by PCR with primer Fal 3.s (5-TAAT CCC GGG GGT CCA TTC
TABLE 1. E64d-mediated inhibition of oocyst production
Isolate or strain,
expt no., and
treatment
GM
no. of
oocysts
Oocyst
range
No. of
mosquitoes
infected/no.
dissected
%
Mosquitoes
infected
% Oocyst
reduction
Isolate NF54a
Expt 1
1 h
DMSO 94 23–176 20/20 100
E64d 0.01 0–1 1/20 5 100*
E64d 0.0 0 0/20 0 100*
30 min
DMSO 111 34–254 20/20 100
E64d 1.8 0–12 13/20 65 98*
E64d 1.7 0–11 16/19 84 98*
15 min
DMSO 134 39–367 20/20 100
E64d 28 3–95 20/20 100 79*
E64d 17.1 0–79 17/20 85 87*
Expt 2
1 h
DMSO 11 0–81 16/20 80
E64d 0 0–0 0 0 100*
E64d 0 0–0 0 0 100*
30 min
DMSO 21 4–74 20/20 100
E64d 0.9 0–3 13/20 65 96*
E64d 0.3 0–1 6/16 37.5 99*
15 min
DMSO 17 0–54 18/20 90
E64d 5.1 0–21 15/20 75 70*
E64d 1.9 0–11 15/20 75 89*
Strain 3D7b
DMSO 8.74 0–40 15/18 83
E64d, 10 M 14.94 0–31 11/12 92
E64d, 100 M 1.69 0–4 6/14 43 81*
a Mature stage V gametocytes of isolate NF54 were treated for the indicated
times with E64d (100 M) or DMSO alone before being fed to Anopheles
stephensi mosquitoes. Seven days later the midguts were dissected and analyzed
for P. falciparum oocysts. For each independent feeding (16 to 20 mosquitoes/
feeding), the geometric mean (GM) number of oocysts per midgut was calculated
and compared with the geometric mean of the number of oocysts per midgut of
mosquitoes fed the control DMSO-treated gametocytes (percent oocyst reduc-
tion). For each treatment the range of the numbers of oocysts per mosquito and
the number and percentage of the dissected mosquitoes that contained one or
more oocysts are listed. *, significant difference (P  0.00) by Kruskal-Wallis
analysis.
b Mature stage V gametocytes of strain 3D7 were treated for 1 h with DMSO
or E64d at the indicated concentrations before being fed to Anopheles stephensi
mosquitoes. Seven days later the midguts were dissected and analyzed for P.
falciparum oocysts. The geometric mean of the number of oocysts per midgut was
calculated for each treatment and compared with the geometric mean of the
number of oocysts per midgut of mosquitoes fed the control DMSO-treated
gametocytes (percent oocyst reduction). For each treatment the range of the
number of oocysts per mosquito and the number and percentage of the dissected
mosquitoes that contained one or more oocysts are listed. *, significant difference
(P  0.00) by Kruskal-Wallis analysis.
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AAA ACA TTA TCA) and primer Fal 3.a (5 TAAT GTC GAC TTC AAG
TAA TGG TAC ATA TGC) and then digested with SmaI and SalI and was then
inserted into StuI- and SalI-digested PIH902 (a generous gift of Paul Riggs, New
England Biolabs, Beverly, MA). The plasmids were used to transform Esche-
richia coli strain DH10B, and once the sequence was confirmed by automated
sequencing (University of Chicago, Chicago, IL), recombinant protein produc-
tion was induced with isopropyl 	-D-thiogalactopyranoside (0.1 mM). The re-
combinant protein was purified on amylose resin (New England Biolabs) emul-
sified in monophosphoryl lipid A plus trehalose dicorynomycolate (Sigma) and
was used to vaccinate mice (38).
Immunoassays. (i) Immunoblotting. The protein expression patterns of fal-
cipain 2A/B and 3 were tested with asexual P. falciparum parasites and throughout
the induction and maturation of gametocytes (Fig. 1). Parasites from asexual
stock cultures or parasites obtained at the indicated times (days 4 to 14) after the
gametocyte cultures were set up were isolated by centrifugation (at 2,000  g for
5 min) after RBC lysis with 0.015% saponin. The cell pellets were washed in
phosphate-buffered saline (PBS) and then extracted in NETT (150 mM NaCl, 5
mM EDTA, 0.5% Triton X-100, 50 mM Tris-Cl [pH 6.8]). SDS sample buffer
(final concentrations, 1% SDS, 10% glycerol, and 125 mM Tris-Cl [pH 6.8]) was
added to the NETT parasite extract or directly to emergence medium which was
isolated by centrifugation (at 2,000  g for 5 min) 1 h after the induction of
gamete/zygote formation. The sample was size fractionated on a 12% polyacryl-
amide gel (Invitrogen) and then transferred to nitrocellulose. The nitrocellulose
blot was incubated with the indicated primary antibodies (1:1,000) and visualized
with alkaline phosphatase-conjugated secondary antibodies (1:2,000; Sigma), 5-bromo-
4-chloro-3-indolyl phosphate p-toluidine salt, and nitroblue tetrazolium chloride
(Promega, Madison, WI).
(ii) Indirect immunofluorescence assay. Monolayers of parasites were air
dried and then fixed in dry ice-chilled methanol, rinsed with PBS, blocked in 5%
nonfat dry milk–PBS, and incubated for 1 h at RT with the indicated serum or
monoclonal antibody. Following two rinses with PBS, the monolayer was incu-
bated for 30 min at RT with a 1:200 dilution of secondary antibody labeled with
tetramethylrhodamine isothiocyanate or fluorescein isothiocyanate and then
rinsed, mounted in Vectashield with or without 4,6-diamidino-2-phenylindole
(DAPI; Vector Labs, Burlingame, CA), and examined by fluorescence micros-
copy.
RESULTS
Expression of falcipains 2A, 2B, and 3 during gametocyto-
genesis. Falcipain 1, 2A/B, and 3 mRNA levels have previously
been determined by Northern and microarray analyses to have
distinct patterns through the life cycle (8, 39). However, as
recently demonstrated by Mair et al. (15), the production of
mRNA and protein can be differentially regulated in Plasmo-
dium. Therefore, we directly evaluated protein expression at
2-day intervals through gametocytogenesis by immunoblotting
using antibodies against falcipain 2A/B (generously provided
by P. Rosenthal) and falcipain 3 (produced as described in
Materials and Methods) (Fig. 1). Since falcipains 2A and 3 are
68% similar at the amino acid level, samples from an asexual
parasite culture were run on the same polyacrylamide gel, and
the resulting immunoblot was probed separately with antibod-
ies against falcipain 2B/A or falcipain 3 to establish specificity.
Under reducing conditions, distinct bands corresponding to 33
kDa with anti-falcipain 3 antibodies and 32 kDa with anti-
falcipain 2A/B antibodies were observed (Fig. 1A). Following
the induction of gametocytogenesis and the inhibition of fur-
ther asexual growth by the addition of n-acetylglucosamine
to the cultures, the expression of falcipain 2A/B decreased
(Fig. 1B). In contrast, falcipain 3 expression remained constant
following the induction of gametocytogenesis. The slight de-
crease in falcipain 3 expression on day 6 corresponds to a
marked decrease in schizonts and an increase in ring-stage
parasites, which are known to express less falcipain 3. Indirect
immunofluorescence assay with the same antibodies indicated
that during gametocytogenesis falcipain 3 is transported out of
the gametocyte into the RBC (Fig. 1C and 2). In mature stage
V gametocytes, falcipain 3 was found to accumulate in vesicles
along the RBC membrane.
Effect of cysteine protease inhibitor E64d on gametogenesis
and oocyst production. To evaluate the role of falcipain 3 in
gametogenesis, we attempted disruption by targeted integra-
tion but were unsuccessful. Similar attempts by other groups
(32) have also been unsuccessful. It is possible that falcipain 3,
unlike falcipain 1, 2A, or 2B, is essential for asexual growth;
and thus, knockout parasites cannot be recovered. As an al-
ternative, we tested the effect of the cysteine protease inhibitor
E64d on gametogenesis and oocyst production, since it had
previously been shown to inhibit P. falciparum surface antigen
Pfs230 processing during gametogenesis (3). The addition of
E64d to mature gametocyte cultures 1 h before the parasites
were harvested by centrifugation, mixed with an equal volume
FIG. 1. Falcipain 2A/B and 3 expression. (A and B) Immunoblots
of NETT extracts of parasites isolated from cultures containing
(A) asexual parasites (Asex) or (B) parasites isolated on the indicated
day were probed with anti-falcipain 2A/B (Fal 2)- or falcipain 3 (Fal
3)-specific antibodies, as described in Materials and Methods.
n-Acetylglucosamine was added on day 8 to block further asexual
growth, and the most abundant gametocyte stage (stages II to V) at
each time point is indicated. (C) Immunofluorescence assay of a meth-
anol-fixed schizont and stage V gametocyte probed with anti-falcipain
3 antibodies and DNA staining with DAPI. The merged anti-falcipain
3 and DAPI-stained DNA images and the corresponding bright-field
(BF) image are shown.
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of human serum, and then fed to mosquitoes significantly re-
duced oocyst production by 80 to 100% (Table 1 [see also Fig.
4A]). A similar 1-h incubation with the carrier dimethyl sulf-
oxide (DMSO) had no significant effect on mosquito infectiv-
ity. The effectiveness of E64d decreased with shorter incuba-
tion times, but even a 15-min treatment inhibited oocyst
production by 79 to 83% (Table 1). In contrast, there was no
inhibition of oocyst production when the concentration of
E64d was reduced to 10 M (Table 1).
Importantly, treatment with 100 M E64d for an hour did
not affect the morphology of the gametocytes or their ability to
respond to conditions that simulate the mosquito midgut
(30°C, pH 8.3, 100 M xanthurenic acid) (Fig. 3). Both
DMSO- and E64d-treated gametocytes rounded up and
emerged from RBCs, and within 10 min, male gametocytes had
completed three rounds of DNA replication and had begun to
exflagellate. During exflagellation one male produced up to
eight motile flagella. In addition, uninfected RBCs formed
clusters around the main body of the exflagellating male, gen-
erating exflagellation centers (Fig. 3). The number of exflag-
ellation centers per 40 field ranged from 0 to 3 for both the
DMSO- and E64d-treated gametocytes. However, as shown
previously (3), E64d treatment effectively inhibited the produc-
tion of the 300-kDa and 35-kDa forms of gametocyte surface
protein Pfs230 during RBC emergence (Fig. 4B). Consistent
with the findings presented in earlier reports (3), there was no
change in the production or release of the 47-kDa form of
Pfs230 following E64d treatment. These data suggest that the
FIG. 2. Localization of falcipain 3 during gametocytogenesis by immunofluorescence assay of stage II, III, IV, and V P. falciparum gametocytes.
The methanol-fixed gametocytes were probed with anti-falcipain 3 and anti-glycophorin A antibodies and tetramethylrhodamine isothiocyanate-
or fluorescein isothiocyanate-labeled secondary antibodies. The bright-field (BF), anti-falcipain 3 (Fal 3), and merged anti-falcipain 3 and
anti-glycophorin A (merge) images are shown.
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effects of E64d treatment are due primarily to cysteine pro-
tease inhibition and not to generalized toxicity.
Effects of additional falcipain inhibitors on gametogenesis
and oocyst production. E64d is a broad-spectrum cysteine pro-
tease inhibitor, and while it is useful for determination of the
functional role of cysteine proteases, it is not specific enough to
be used therapeutically. To identify a more specific P. fal-
ciparum inhibitor, a number of other compounds are being
screened for their abilities to block asexual growth and/or
falcipain activity (5, 16, 22). Several compounds that effectively
inhibit recombinant falcipains 2A, 2B, and 3 have been devel-
oped and have been tested for their effects on asexual growth,
but they have never been screened against sexual stage para-
sites (10, 17, 29). Two compounds, Mu-Leu-hPhe-VSPh and
Mu-Leu-hPhe-FMK (generously provided by P. Rosenthal),
that effectively inhibit falcipain 2B and 3, as well as YA29,
which was reported to preferentially inhibit falcipain 1, were
used to treat mature gametocyte cultures (10, 17, 29). How-
ever, none of these significantly inhibited oocyst production
following a 1- to 2-h incubation (Fig. 4A). Under the condi-
tions used for feeding, none of these compounds blocked ga-
metogenesis, exflagellation, or the production of the 35-kDa
Pfs230 fragment (Fig. 4B). In some preparations an additional
fragment, which is 
2 kDa larger than the 47-kDa form, was
present in the same samples that contained the 35-kDa frag-
ment and was absent from the samples that did not contain the
35-kDa fragment. This pattern could suggest that the 35-kDa
form is a fragment of the 49-kDa form and that the extent of
further processing of the 49-kDa form to the 35-kDa form
varies between preparations of supernatants from emerged
parasites.
To evaluate whether accessibility to the target protease lim-
ited the effectiveness of the drugs, 0.001% saponin was added
to permeabilize, but not solubilize, the RBC membrane. In the
presence of 0.001% saponin, Mu-Leu-hPhe-FMK, but not the
vinyl phenol sulfone derivative, Mu-Leu-hPhe-VSPh, inhibited
Pfs230 processing (Fig. 4B). Pretreatment with 0.001% sapo-
FIG. 4. Effects of cysteine protease inhibitors on oocyst production
and Pfs230 processing. (A) Feeding protease inhibitor-treated game-
tocytes to mosquitoes. Mature gametocytes of strain 3D7 were treated
for 1 h with the indicated protease inhibitor, YA29, E64d, Mu-Leu-
hPhe-VSPh (VSP), or Mu-Leu-hPhe-FMK (FMK), or DMSO alone
before they were fed to Anopheles stephensi mosquitoes. Seven days
later the midguts were dissected and analyzed for P. falciparum oo-
cysts. For each independent feeding (11 to 22 mosquitoes per feeding),
the average number of oocysts per midgut was calculated for each
treatment and compared with the average number of oocysts per
midgut of mosquitoes fed the control DMSO-treated gametocytes
(percent oocyst reduction). *, significant difference (P  0.007) from
the results for the DMSO-treated control by Kruskal-Wallis analysis.
(B) Pfs230 processing during emergence following protease inhibitor
treatment in the presence and absence of 0.001% saponin. Following
a 1-h incubation in the presence or absence of 0.001% saponin with
DMSO alone (D) or the indicated protease inhibitor, YA29 (Y), Mu-
Leu-hPhe-VSPh (V), Mu-Leu-hPhe-FMK (F), 100 M E64d (E), or
10 M E64d (E10), mature gametocytes were pelleted and stimulated
to emerge as described in Materials and Methods. The emergence
medium was harvested, size fractionated, immunoblotted, and probed
with Pfs230 region A (aa 304 to 378)-specific antibodies. The arrows
indicate the 47-kDa and 35-kDa fragments.
FIG. 3. Gametogenesis following E64d treatment. Mature gameto-
cytes (G’cytes) of strain 3D7 were incubated for 1 h with E64d or an
equivalent volume of DMSO. The gametocytes were then pelleted and
gametogenesis was induced by adding an equal volume of emergence
medium. Giemsa-stained thin smears of samples obtained before the
stimulus (preemergence) and 15 min after the stimulus (postemer-
gence) are shown, as are bright-field images of the exflagellation cen-
ters that were observed 15 to 30 min after the stimulus. Arrows indi-
cate the exflagellating male parasite(s) in the exflagellation (Exflag)
center.
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nin also decreased the concentration of E64d required to in-
hibit Pfs230 processing to 10 M but had no effect on game-
togenesis or exflagellation. These findings demonstrate that
both the inhibitor specificity and the accessibility of the pro-
tease(s) involved in Pfs230 processing and oocyst production
are distinct from those observed for inhibition of hemoglobin
digestion during asexual growth.
DISCUSSION
Pretreatment of stage V gametocytes with the membrane-
permeant cysteine protease inhibitor E64d for 1 h was found to
significantly inhibit oocyst production and, as reported previ-
ously (3), the production of the 300-kDa and 35-kDa forms of
gametocyte surface protein Pfs230. Treatment does not affect
the morphology of the gametocytes or their ability to round up
and emerge from the RBC minutes after being stimulated.
Additionally, E64d-treated male parasites were still able to
exflagellate within 10 to 15 min of application of the emer-
gence stimulus and to form exflagellation centers. Since exflag-
ellation is one of the most dynamic processes of the parasite
life cycle (for a video, see reference 9), maintenance of this
function following E64d treatment suggests that the gameto-
cytes remained viable. Therefore, the subsequent reduction in
oocyst production is most likely due to the inhibition of cys-
teine proteases and not to general toxicity.
None of the other more specific inhibitors that have been
found to inhibit one or more of the P. falciparum falcipains,
Mu-Leu-hPhe-FMK, Mu-Leu-hPhe-VSPh, or YA29, signifi-
cantly reduced oocyst production or Pfs230 processing (Fig. 4).
Lower concentrations of E64d also did not effectively inhibit
oocyst production or the production of the 35-kDa form of
Pfs230 in the absence of saponin (Fig. 1B and 4B). However,
an increase in the permeability of the RBC without RBC
disruption by addition of 0.001% saponin enhanced the abili-
ties of both Mu-Leu-hPhe-FMK and E64d to inhibit Pfs230
processing. This suggests that there is limited accessibility to
the target protease in intact gametocytes, which may contrib-
ute to the need for such high external drug concentrations.
Accessibility could be a major difference between the targeting
of proteases in the food vacuole, which is actively taking up
material from the RBC, and the targeting of proteases located
in other compartments in the parasite. Target protease access
and specificity may be important factors to be considered in
future drug optimization studies. As demonstrated by these
findings, inhibition of the cysteine proteases involved in hemo-
globin digestion has requirements different from those for the
inhibition of the cysteine proteases involved in oocyst produc-
tion.
The inability of Mu-Leu-hPhe-VSPh to inhibit Pfs230 pro-
cessing even in the presence of saponin may also suggest that
the target protease is less sensitive to Mu-Leu-hPhe-VSPh
than Mu-Leu-hPhe-FMK or that an active form of Mu-Leu-
hPhe-VSPh may not have access to the P. falciparum gameto-
cyte compartment where processing takes place. The cysteine
proteases involved in oocyst production and/or Pfs230 process-
ing have not yet been identified. Falcipain 2A/B is an unlikely
candidate, since the data presented here demonstrate that
mature gametocytes lack falcipain 2A/B protein expression.
Falcipain 1 may be involved, as its targeted disruption signifi-
cantly reduces oocyst production; but E64d-induced inhibition
is much more effective, suggesting that additional cysteine pro-
teases are involved (8). Falcipain 3 is a possible candidate, as
it is expressed at the appropriate time and location and its
ability to cleave a fluorogenic substrate is 2  102 times more
sensitive to inhibition by Mu-Leu-hPhe-FMK (5,850,000 
15,800 M1 s1) than by Mu-Leu-hPhe-VSPh (22,000  1,420
M1 s1) (17). This differential sensitivity is consistent with the
lack of an effect of Mu-Leu-hPhe-VSPh on Pfs230 processing
even in the presence of 0.001% saponin. However, the involve-
ment of other E64d-sensitive P. falciparum cysteine proteases
remains a possibility.
The findings reported here, coupled with the findings of
previous work demonstrating an important role of cysteine
proteases in trophozoite growth, merozoite release, oocyst rup-
ture, and sporozoite invasiveness, demonstrate the therapeutic
potential of cysteine protease inhibitors to significantly reduce
both the morbidity from malaria and the transmission of the
malaria parasite (1, 4, 10, 23, 25, 28, 30, 34, 37). Identifying the
proteases expressed in both the asexual and the sexual stages
and their in vivo accessibilities to inhibitors is an important
component of drug development. Previous work has impli-
cated falcipains 2A/B and 3 in asexual hemoglobin digestion
and, possibly, RBC emergence, and recombinant falcipains 2A
and 3 have been used in a number of drug screening assays (6,
7, 11, 29, 31, 33, 34). The data from this study demonstrating
that gametocytes express falcipain 3 and not falcipain 2A/B,
coupled with the possibility that falcipain 3 could be essential
for asexual growth, suggest that falcipain 3 is a prime drug
target. Falcipain 1 has also been shown to be expressed by
gametocytes and to play a role in oocyst production and there-
fore should also be included in drug development efforts (8).
The differential effectiveness of the three additional falcipain
inhibitors compounds tested here, Mu-Leu-hPhe-FMK, Mu-
Leu-hPhe-VSPh, and YA29, on asexual growth and oocyst
production highlights the importance of including the sexual
stages in the evaluation of new therapeutic candidates.
In summary, this work indicates that cysteine proteases are
important for sexual stage parasite function. The development
of inhibitors that effectively target the asexual and the sexual
stages has the potential to effectively block the morbidity
caused by the malaria parasite as well as transmission of the
malaria parasite.
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